McKesson Corporation
MCK · Price history
Price at last available close
$960.56
+$104.27 (+12.18%) 1M
2026-10-28
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About McKesson Corporation
Primary reporting period: 2026-03-31 · Research updated Oct 7, 2026. A research update is not a new financial filing.
Who they are
McKesson Corporation is a prominent global provider of healthcare services, operating extensively in both the United States and international markets. Its diverse operations are strategically organized into four key business segments. The U.
How they make money
McKesson is a diversified healthcare services leader that operates through a distribution and services model. The company generates revenue primarily by distributing pharmaceuticals and medical-surgical supplies to healthcare providers, pharmacies, and health systems, while also providing technology solutions and specialized services for oncology and multispecialty practices.
Products & services
Pharmaceutical distribution, medical-surgical supply distribution, oncology and multispecialty practice management services, and prescription technology solutions.
Brands & revenue mix
No separate brand or brand-level revenue disclosure was confirmed in the reviewed sources. This does not mean the company has no brands.
Product / operating segments
Period ended 2026-03-31Source
Period ended 2026-03-31Source
Period ended 2026-03-31Source
Period ended 2026-03-31Source
Period ended 2026-03-31Source
Calculated from reported segment revenue. Check the source period and revenue basis before comparing shares. Categories can overlap and may not add to 100%.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer concentration
The company discloses that it has significant customer concentration, noting that its largest customer accounted for a material portion of its consolidated revenues for the fiscal year ended March 31, 2026.
Suppliers, materials & equipment
- Pharmaceutical manufacturers — The company sources pharmaceutical products from a wide range of manufacturers.Source
Competitors
Strengths
- Extensive distribution network and scale in the healthcare supply chainSource
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
55
Fair
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
65
Fair
Financial Strength
40
Business Quality / Moat
89
Management
80
Growth Quality
37
Risk / Durability
94
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
57
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
58/100
Building Historical Record
Model Score 58/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is mixed across its combined quality, valuation and risk inputs. Review the category scores to identify what is helping or hurting the result.
At today’s price, the WSS valuation framework currently reads as moderate rather than unusually attractive.
The model outlook is currently moderate.
- •Valuation scores attractively
- •Recent buyback activity is present
- •M&A headline · Oct 6, 2026
- •Revenue fundamentals are weak
- •Debt / balance-sheet profile needs attention
Company-specific research
Questions worth answering for MCK
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can MCK maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •Is MCK's positive free cash flow repeatable, or is the current level being helped by temporary working-capital or spending changes?
- •Is MCK's debt load manageable relative to cash generation, interest costs and upcoming maturities?
- •Is MCK's valuation discount tied to a temporary concern or to a longer-term business risk?
Essential Investment Snapshot
Wall Street Score
55
Opportunity Score
57
Market Cap
$111.99B
P/E Ratio
24.2
EPS
$37.53
52-Week High
$999.00
52-Week Low
$723.68
Beta
0.31
Intrinsic Value
$1324.17
Analyst Target
$966.50
Shares Outstanding
124.1M
Total Revenue
$410.98B
Total Debt
$11.70B
Dividend Yield (TTM)
0.35%
Liquidation Value / Share
$-31.14
Dividend / Share (TTM)
$3.40
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Neutral / mixed momentum
Low movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for MCK
Detected from reported data — verify before acting.Dividend history reported
Dividend payments are recorded. Review the dates and regular/special classification below; past payments do not guarantee future dividends.
Historical repurchase activity
Reported cash flows or share-count measures indicate past repurchase activity. This does not verify an active buyback authorization or future purchases.
M&A headline · Oct 6, 2026
McKesson and CD&R agree to acquire Option Care Health for $5.8 billion — This is a provider-linked headline, not an independently confirmed event. Check the article and company filings for the subject, proposed/completed status, and subsequent updates.
Proactive InvestorsM&A headline · Oct 6, 2026
CD&R, McKesson to Acquire At-Home Infusion Therapy Provider for $5.8 Billion — This is a provider-linked headline, not an independently confirmed event. Check the article and company filings for the subject, proposed/completed status, and subsequent updates.
WSJCommunity Sentiment
0 active · 0 total callsNo personal call yet on MCK.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Extensive distribution network and scale in the healthcare supply chain.
- +Positive free cash flow may provide capacity to invest in growth.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Medical - Distribution industry.
- −Significant customer concentration.
- −Regulatory changes in the healthcare industry.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
3 historical score records availablePrevious Score
57
Oct 1, 2026
Change
-2.1
points
Current Score
55
Oct 5, 2026
Category Changes
MCK decreased 2.1 points because Capital declined by 4 points, Valuation declined by 7.5 points.
Negative Contributors
- − Capital declined by 4 points
- − Valuation declined by 7.5 points
Projected Score
Projected Score
51
Projected Change
-4.0 points
Preliminary comparable-period financial changes suggest decline of approximately 4.0 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
UndervaluedCurrent Price
$960.56
Model Intrinsic Value
$1324.17
Difference
−$363.61
-27.5% vs IV
Margin of Safety
27.5%
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $410.98B | $403.43B | $359.05B | $308.95B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $396.03B | $388.88B | $346.57B | $296.75B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | $14.96B | $14.55B | $12.48B | $12.20B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $0.00 | $103.0M | $91.0M | $77.0M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $4.10B | -$8.10B | $8.02B | $8.20B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $8.30B | $8.10B | $8.11B | $8.28B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | $7.14B | $7.18B | $5.25B | $4.67B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | $6.65B | $6.45B | $4.37B | $3.93B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $153.0M | $247.0M | $256.0M | $243.0M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | $6.46B | $6.20B | $4.36B | $3.79B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | $1.16B | $1.10B | $878.0M | $629.0M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | $4.59B | $4.76B | $3.29B | $3.00B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $37.53 | $38.55 | $25.86 | $22.54 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 119M | 124M | 127M | 133M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 119M | 124M | 128M | 134M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$105.38B
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
$5.15
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
+17.8%
Cash Change
+113.6%
Margin Change
-0.2 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Cash position grew
What Weakened
- Margins contracted
- Debt increased
Potential Score Impact
Positive indicators included revenue growth, cash levels. Pressure indicators included EPS growth, debt levels, net income margin. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue increased 7.7%. EPS declined 17.6%. Cash increased 113.6%. Total debt increased 17.8%. Net income margin declined by 0.2 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
63
Smart Money
63
Number of Gurus
7
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Log in to view dividend history.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
3 historical recordsHistorical Score Chart
3 of 3 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
Medical - DistributionNews
McKesson (MCK) Earnings Expected to Grow: Should You Buy?
Here's Why McKesson (MCK) is a Strong Momentum Stock
McKesson: AI And FDA Overhaul Likely To Overtake Regulatory Drag In 2027
Is Trending Stock McKesson Corporation (MCK) a Buy Now?
Rumor Mill · MCK
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial